Guardant360 tissue next
GUARDANT360® PATIENT GUIDE
Find treatment options with the ease of a blood draw
Guardant360®
is a blood test that helps your doctor decide which therapy may be right for you
Results in about 7 days
Your doctor will receive the results in about 7 days from receipt at the laboratory
Insurance may cover Guardant360®
Check with our Client Services team if your insurer is on the list
Your doctor may order Guardant360® when:
- Tumour testing of your initial tissue biopsy is incomplete or inconclusive.
- Your cancer is progressing on the current treatment.
If you have any questions, please contact our Client Service team to get the answers.
Contact usFind treatment options
For patients with advanced cancers, targeted therapies can provide promising new treatment options. But a clear genomic picture is needed for your doctor to consider your best treatment options.
Traditionally, a tissue biopsy was the only way to access this information. The Guardant360® liquid biopsy may provide this information with the ease of a blood draw.
Seeing the full picture
As a blood test, Guardant360® captures the DNA that is shed f
Testing Across the
Continuum of Cancer
A comprehensive portfolio of liquid and tissue precision oncology tests for patients diagnosed with early or advanced-stage cancer.
Expanded Liquid Testing With Genomic and Epigenomic Insights
Guardant360 Liquid is the first and only liquid biopsy to deliver genomic and epigenomic insights for a more complete view of cancer.1 By analyzing cell-free DNA, Guardant360 Liquid helps healthcare providers detect actionable genomic and epigenomic alterations to guide personalized treatment and monitor tumor evolution. Guardant360 Liquid is guideline-recommended across all advanced solid tumors and has broad commercial and Medicare coverage for advanced solid tumors.
A Fast CGP Panel With Guideline-Recommended Actionable Biomarkers
Guardant360 CDx is our FDA-approved liquid biopsy that provides results in less than 7 days to inform treatment decisions.2 Guardant360 CDx has broad commercial and Medicare coverage for all advanced solid tumors.3
Unlock Maximum Insights From Minimal Tissue With Advanced Multiomics
Guardant360 Tissue is a multiomic test for patients with advanced solid tumors, p
Test Procedure: Help
gDNA is isolated from paraffin-embedded in tissue. Tracking DNA library preparation, next generation sequencing of specific gene regions is performed. Reports provide details of variants detected and any relevant clinical information.
Test Platform:
None/not applicable
Test Comments: Help
The test detects unattached nucleotide variants in a targeted panel of 84 genes, and selected copy number amplifications, fusions/rearrangements, and indels for a specific set of genes. All four types of genomic alterations are reported in a single evaluate.
The following genes are sequenced: AKT1; ALK; APC; AR; ARAF; ARID1A; ATM; BRAF; BRCA1; BRCA2; CCND1; CCND2; CCNE1; CDH1; CDK4; CDK6; CDK12; CDKN2A; CHEK2; CTNNB1; DDR2; EGFR; ERBB2; ESR1; EZH2; FANCA; FBXW7; FGFR1; FGFR2; FGFR3; GATA3; GNA11; GNAQ; GNAS; HNF1A; HRAS; IDH1; IDH2; JAK2; JAK3; KEAP1; KIT; KRAS; MAP2K1; MAP2K2; …The following genes are sequenced: AKT1; ALK; APC; AR; ARAF; ARID1A; ATM; BRAF; BRCA1; BRCA2; CCND1; CCND2; CCNE1; CDH1; CDK4; CDK6; CDK12; CDKN2A; CHEK2; CTNNB1; DDR2; EGFR; ERBB2; ESR1; EZH2; FANCA; FBXW7; FGFR1; FGFR2; FGFR3; GATA3; GNA11; GNAQ; GNAS; HNF1A; HRAS; IDH1; IDH2; JAK2; JAK3
1
Tissue-based test for complete genomic testing across all advanced solid cancers
Guardant360 TissueNextTM is a next-generation sequencing (NGS)-based pan-cancer tissue test for patients with advanced solid tumor. The test allows oncologists to identify actionable biomarkers for therapeutic management.
The Guardant360 TissueNextTM test report covers 84 genes and will include Tumor Mutational Burden (TMB), Microsatellite Instability (MSI) status, Homologous Recombination Repair (HRR) genes and selected fusions.
Contact us for any enquiries
Alterations covered
Guardant360 TissueNext covers alterations in 84 genes relevant to multiple solid tumors, also TMB and MSI status.
21 days upon sample receipt in the US laboratory.
Ship same or next day at room temperature. Do not freeze or refrigerate.
The process
Place an order with Guardant Health's designated local partner - Codex Genetics.
Provide tumor tissue samples of patients.
Samples will be sent to Guardant Health laboratary in the United States.
Complete genomic result in 21 days upon sample receipt in the US laboratory.
Download Resources
Guardant360 PatGuardant Complete™
Testing Across the Continuum of Cancer
Expanded Liquid Testing With Genomic and Epigenomic Insights
Guardant360 Liquid is the first and only liquid biopsy to deliver genomic and epigenomic insights for a more complete view of cancer.1 By analyzing cell-free DNA, Guardant360 Liquid helps healthcare providers detect actionable genomic and epigenomic alterations to guide personalized treatment and monitor tumor evolution.
A Fast CGP Panel with Guideline-Recommended Actionable Biomarkers
Our Guardant360 CDx test is our FDA-approved liquid biopsy that provides results in 7 days upon sample receipt in the laboratory to inform treatment decisions.2
Unlock Maximum Insights From Minimal Tissue With Advanced Multiomics
Guardant360 Tissue is a multiomic test for patients with advanced solid tumors, providing comprehensive genomic, transcriptomic, and epigenomic insights3 using minimal tissue—requiring 92% less surface area4 and 40% fewer slides than the industry standard.5
Minimal Residual Disease Detection and Recurrence Monitoring
Guardant Reveal is a blood-only test without tissue base